Sana Anwar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sana Anwar has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Abdul Subhan Talpur
Internal Medicine, United Health Services (UHS) Wilson Medical Center, Johnson City, USA
4 shared publications Farukhzad Hafizyar
Internal Medicine, Ariana Sabet Hospital, Kabul, AFG
3 shared publicationsDaniya Muhammad Haroon
Internal Medicine, Bahria University Medical & Dental College, Karachi, PAK
2 shared publicationsEmilia E. Jones Amaowei
Clinical Affairs, Dexcom Inc, San Diego, USA
2 shared publications- Firas Kadurei
Internal Medicine, Mubarak Al-Kabeer Hospital, Jabriya, KWT
2 shared publications - Kefayatullah Nazary
Internal Medicine, Kabul University of Medical Sciences, Kabul, AFG
2 shared publications
Latest Publications
- Open Access
- 22 October 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (12) , 7202-7211
Role of artificial intelligence in predicting neurological outcomes in postcardiac resuscitation
Being an extremely high mortality rate condition, cardiac arrest cases have rightfully been evaluated via various studies and scoring factors for effective resuscitative practices and neurological outcomes postresuscitation. This narrative review aims to explore the role of artificial intelligence (AI) in predicting neurological outcomes postcardiac resuscitation. The methodology involved a detailed review of all relevant recent studies of AI, different machine learning algorithms, prediction tools, and assessing their benefit in predicting neurological outcomes in postcardiac resuscitation cases as compared to more traditional prognostic scoring systems and tools. Previously, outcome determining clinical, blood, and radiological factors were prone to other influencing factors like limited accuracy and time constraints. Studies conducted also emphasized that to predict poor neurological outcomes, a more multimodal approach helped adjust for confounding factors, interpret diverse datasets, and provide a reliable prognosis, which only demonstrates the need for AI to help overcome challenges faced. Advanced machine learning algorithms like artificial neural networks (ANN) using supervised learning by AI have improved the accuracy of prognostic models outperforming conventional models. Several real-world cases of effective AI-powered algorithm models have been cited here. Studies comparing machine learning tools like XGBoost, AI Watson, hyperspectral imaging, ChatGPT-4, and AI-based gradient boosting have noted their beneficial uses. AI could help reduce workload, healthcare costs, and help personalize care, process vast genetic and lifestyle data and help reduce side effects from treatments. Limitations of AI have been covered extensively in this article, including data quality, bias, privacy issues, and transparency. Our objectives should be to use more diverse data sources, use interpretable data output giving process explanation, validation method, and implement policies to safeguard patient data. Despite the limitations, the advancements already made by AI and its potential in predicting neurological outcomes in postcardiac resuscitation cases has been quite promising and boosts a continually improving system, albeit requiring close human supervision with training and improving models, with plans to educate clinicians, the public and sharing collected data.
- 22 October 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (12) , 7202-7211
Open AccessRole of artificial intelligence in predicting neurological outcomes in postcardiac resuscitation
Being an extremely high mortality rate condition, cardiac arrest cases have rightfully been evaluated via various studies and scoring factors for effective resuscitative practices and neurological outcomes postresuscitation. This narrative review aims to explore the role of artificial intelligence (AI) in predicting neurological outcomes postcardiac resuscitation. The methodology involved a detailed review of all relevant recent studies of AI, different machine learning algorithms, prediction tools, and assessing their benefit in predicting neurological outcomes in postcardiac resuscitation cases as compared to more traditional prognostic scoring systems and tools. Previously, outcome determining clinical, blood, and radiological factors were prone to other influencing factors like limited accuracy and time constraints. Studies conducted also emphasized that to predict poor neurological outcomes, a more multimodal approach helped adjust for confounding factors, interpret diverse datasets, and provide a reliable prognosis, which only demonstrates the need for AI to help overcome challenges faced. Advanced machine learning algorithms like artificial neural networks (ANN) using supervised learning by AI have improved the accuracy of prognostic models outperforming conventional models. Several real-world cases of effective AI-powered algorithm models have been cited here. Studies comparing machine learning tools like XGBoost, AI Watson, hyperspectral imaging, ChatGPT-4, and AI-based gradient boosting have noted their beneficial uses. AI could help reduce workload, healthcare costs, and help personalize care, process vast genetic and lifestyle data and help reduce side effects from treatments. Limitations of AI have been covered extensively in this article, including data quality, bias, privacy issues, and transparency. Our objectives should be to use more diverse data sources, use interpretable data output giving process explanation, validation method, and implement policies to safeguard patient data. Despite the limitations, the advancements already made by AI and its potential in predicting neurological outcomes in postcardiac resuscitation cases has been quite promising and boosts a continually improving system, albeit requiring close human supervision with training and improving models, with plans to educate clinicians, the public and sharing collected data.
- Open Access
- 27 March 2024
- Published by IntechOpen
What comes before scleroderma?
While the classification criteria for systemic sclerosis (SSc) have been carefully delineated, the definition of what comes before meeting classification criteria is not so well understood. In some ways, it is similar to pre-rheumatoid arthritis where a reasonable definition has been developed and the downstream early treatment of pre-rheumatoid arthritis is being tested. However, for SSc, there may well be a very early SSc phase before any, but constitutional symptoms occur. This preclinical phase is very poorly understood or described. The very early diagnosis of systemic sclerosis (VEDOSS) has been defined, but there remain multiple questions surrounding VEDOSS, including when and how to treat patients with this diagnosis. Despite progress, there are no fully validated biomarkers or genetic predictors for disease evolution. Moreover, although VEDOSS patients with Raynauds phenomenon (RP), autoantibodies and SSc capillaroscopic pattern could be easily followed up, and no targeted cohort study to achieve these ends has been developed. Such a cohort study is very much needed, but it would require documenting all appropriate clinical, genetic, and autoimmune measures, followed for at least 5 and perhaps more years, using a randomized menu of treatments.
- 27 March 2024
- Published by IntechOpen
Open AccessWhat comes before scleroderma?
While the classification criteria for systemic sclerosis (SSc) have been carefully delineated, the definition of what comes before meeting classification criteria is not so well understood. In some ways, it is similar to pre-rheumatoid arthritis where a reasonable definition has been developed and the downstream early treatment of pre-rheumatoid arthritis is being tested. However, for SSc, there may well be a very early SSc phase before any, but constitutional symptoms occur. This preclinical phase is very poorly understood or described. The very early diagnosis of systemic sclerosis (VEDOSS) has been defined, but there remain multiple questions surrounding VEDOSS, including when and how to treat patients with this diagnosis. Despite progress, there are no fully validated biomarkers or genetic predictors for disease evolution. Moreover, although VEDOSS patients with Raynauds phenomenon (RP), autoantibodies and SSc capillaroscopic pattern could be easily followed up, and no targeted cohort study to achieve these ends has been developed. Such a cohort study is very much needed, but it would require documenting all appropriate clinical, genetic, and autoimmune measures, followed for at least 5 and perhaps more years, using a randomized menu of treatments.
- Open Access
- 11 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32405
Systematic Review on the Effects of Prompt Antibiotic Treatment on Survival in Septic Shock and Sepsis Patients in Different Hospital Settings
This study aims to determine the impact of prompt administration of antibiotics in evaluating the prognosis of patients with septic shock or sepsis. On January 1, 2022, we searched the Cochrane Library, EMBASE, and MEDLINE databases for English-language articles regarding when antibiotics should be administered to patients with septic shock or sepsis. These articles were required to be published between 2010 and 2021. The primary objective was sudden or expected death from any cause at a specified time. In the study, 154,330 patients from 35 sepsis trials were included. In 19 trials, the effectiveness of antibiotics administered to 20,062 patients was evaluated. Of those, 16,652 received the correct medications. In 24 studies, the length of time it took to administer antibiotics was associated with an increased mortality rate. In fourteen studies, the time limits associated with patient outcomes ranged from 1 to 125 minutes to three to six hours. In eight studies, there were hourly delays, and in two, the time it took to receive an antibiotic played a role. Separately analyzed, the outcomes for septic shock (12,756 patients in 11 trials) and sepsis (24,282 patients in six studies) were identical. Two-thirds of sepsis studies discovered a correlation between early antibiotic treatment and the patient's prognosis. However, antimicrobial timing metrics varied significantly between studies, and there were no clear time limits.
- 11 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32405
Open AccessSystematic Review on the Effects of Prompt Antibiotic Treatment on Survival in Septic Shock and Sepsis Patients in Different Hospital Settings
This study aims to determine the impact of prompt administration of antibiotics in evaluating the prognosis of patients with septic shock or sepsis. On January 1, 2022, we searched the Cochrane Library, EMBASE, and MEDLINE databases for English-language articles regarding when antibiotics should be administered to patients with septic shock or sepsis. These articles were required to be published between 2010 and 2021. The primary objective was sudden or expected death from any cause at a specified time. In the study, 154,330 patients from 35 sepsis trials were included. In 19 trials, the effectiveness of antibiotics administered to 20,062 patients was evaluated. Of those, 16,652 received the correct medications. In 24 studies, the length of time it took to administer antibiotics was associated with an increased mortality rate. In fourteen studies, the time limits associated with patient outcomes ranged from 1 to 125 minutes to three to six hours. In eight studies, there were hourly delays, and in two, the time it took to receive an antibiotic played a role. Separately analyzed, the outcomes for septic shock (12,756 patients in 11 trials) and sepsis (24,282 patients in six studies) were identical. Two-thirds of sepsis studies discovered a correlation between early antibiotic treatment and the patient's prognosis. However, antimicrobial timing metrics varied significantly between studies, and there were no clear time limits.
- Open Access
- 14 March 2022
- Published by Springer Nature in Cureus
- Vol. 14 (3) , e23137
Correlation of Depression and Anxiety With Rheumatoid Arthritis
Psychiatric comorbidity with a chronic disease is linked with poor patient outcomes. Therefore, the current research assessed the correlation of rheumatoid arthritis (RA) with depression and anxiety disorders. A prospective observational study was undertaken at a public sector hospital between December 2020 to June 2021. All individuals who presented with rheumatoid arthritis were included in the study. A healthy cohort acted as the control group. Depression and anxiety were assessed using the Hamilton depression rating scale (HDRS) and the Hamilton anxiety rating scale (HAM-A), respectively. The patients were inquired about their gender, age, and duration of RA. Further stratification was done using the Chi-squared test. A p-value of <0.05 was decided as the cut-off for significance. All data from the patients were collected in a predefined pro forma. A total of 169 patients with RA and 85 healthy controls were enrolled in the study. The mean depression score among patients with RA was 19.65 ± 1.44 versus 14.4 ± 1.31 in the control group (p<0.001). Moreover, the mean anxiety score in patients with RA was 19.44 ± 2.4. About 71% of patients with RA were diagnosed with psychiatric issues, while only 7.1% of individuals in the control group had either depression or anxiety (p<0.0001). Furthermore, it was found that the majority of the patients with RA had depression with a frequency of 70 (58.3%), while only six participants in the control group had depression. None of the participants had moderate or severe depression. However, 16 (69.6%) patients with RA had major anxiety issues. In 27 patients, mixed anxiety-depression disease was diagnosed. Out of these, 23 (85.2%) had the depression-dominant mixed disorder. The present study highlighted the alarming incidence of depression and anxiety among patients with RA. Furthermore, it also indicated the relationship between severity of psychiatric comorbidity with chronic rheumatoid arthritis in our population. Further large-scale studies are needed to ascertain the demographic confounders that may help predict psychiatric disorders among patients with RA.
- 14 March 2022
- Published by Springer Nature in Cureus
- Vol. 14 (3) , e23137
Open AccessCorrelation of Depression and Anxiety With Rheumatoid Arthritis
Psychiatric comorbidity with a chronic disease is linked with poor patient outcomes. Therefore, the current research assessed the correlation of rheumatoid arthritis (RA) with depression and anxiety disorders. A prospective observational study was undertaken at a public sector hospital between December 2020 to June 2021. All individuals who presented with rheumatoid arthritis were included in the study. A healthy cohort acted as the control group. Depression and anxiety were assessed using the Hamilton depression rating scale (HDRS) and the Hamilton anxiety rating scale (HAM-A), respectively. The patients were inquired about their gender, age, and duration of RA. Further stratification was done using the Chi-squared test. A p-value of <0.05 was decided as the cut-off for significance. All data from the patients were collected in a predefined pro forma. A total of 169 patients with RA and 85 healthy controls were enrolled in the study. The mean depression score among patients with RA was 19.65 ± 1.44 versus 14.4 ± 1.31 in the control group (p<0.001). Moreover, the mean anxiety score in patients with RA was 19.44 ± 2.4. About 71% of patients with RA were diagnosed with psychiatric issues, while only 7.1% of individuals in the control group had either depression or anxiety (p<0.0001). Furthermore, it was found that the majority of the patients with RA had depression with a frequency of 70 (58.3%), while only six participants in the control group had depression. None of the participants had moderate or severe depression. However, 16 (69.6%) patients with RA had major anxiety issues. In 27 patients, mixed anxiety-depression disease was diagnosed. Out of these, 23 (85.2%) had the depression-dominant mixed disorder. The present study highlighted the alarming incidence of depression and anxiety among patients with RA. Furthermore, it also indicated the relationship between severity of psychiatric comorbidity with chronic rheumatoid arthritis in our population. Further large-scale studies are needed to ascertain the demographic confounders that may help predict psychiatric disorders among patients with RA.
- Open Access
- 26 September 2021
- Published by Springer Nature in Cureus
- Vol. 13 (9)
Prevalence of Thyroid Dysfunction in Patients With Hepatitis C
Introduction: Hepatitis C has been linked to a multitude of autoimmune disorders, including rheumatoid arthritis, thyroid disease, cryoglobulinemia, immune thrombocytopenic purpura, systemic lupus erythematosus, and Sjögren’s syndrome. In this study, efforts were made to draw a parallel between hepatitis C and thyroid dysfunction. Methods: This case-control study was conducted between June 2020 and March 2021 in the gastroenterology ward of a tertiary care hospital. We enrolled 300 hepatitis C-positive patients in this study through consecutive convenient non-probability sampling. In addition, 300 patients without hepatitis C were signed up as a control group. Blood sampling for thyroid function tests was conducted via phlebotomy from the cubital vein and the samples were dispatched to the laboratory for further study. Results: The control group had more euthyroid patients as compared to patients with hepatitis C (74.6% vs. 89.6%; p-value: <0.01). Hepatitis C patients had more cases of primary hypothyroidism compared to the control group (10.6% vs. 4.6%; p-value: 0.005). Similarly, patients with hepatitis C had a higher prevalence of subclinical hypothyroidism compared to the control group (6.0% vs. 1.3%; p-value: 0.002). Conclusion: Hepatitis C patients have a high frequency of thyroid dysfunction, particularly primary hypothyroidism and subclinical hypothyroidism. Therefore, it is important to ensure regular screening for early prognosis and avoid treatment modalities that are known to cause thyroid abnormalities.
- 26 September 2021
- Published by Springer Nature in Cureus
- Vol. 13 (9)
Open AccessPrevalence of Thyroid Dysfunction in Patients With Hepatitis C
Introduction: Hepatitis C has been linked to a multitude of autoimmune disorders, including rheumatoid arthritis, thyroid disease, cryoglobulinemia, immune thrombocytopenic purpura, systemic lupus erythematosus, and Sjögren’s syndrome. In this study, efforts were made to draw a parallel between hepatitis C and thyroid dysfunction. Methods: This case-control study was conducted between June 2020 and March 2021 in the gastroenterology ward of a tertiary care hospital. We enrolled 300 hepatitis C-positive patients in this study through consecutive convenient non-probability sampling. In addition, 300 patients without hepatitis C were signed up as a control group. Blood sampling for thyroid function tests was conducted via phlebotomy from the cubital vein and the samples were dispatched to the laboratory for further study. Results: The control group had more euthyroid patients as compared to patients with hepatitis C (74.6% vs. 89.6%; p-value: <0.01). Hepatitis C patients had more cases of primary hypothyroidism compared to the control group (10.6% vs. 4.6%; p-value: 0.005). Similarly, patients with hepatitis C had a higher prevalence of subclinical hypothyroidism compared to the control group (6.0% vs. 1.3%; p-value: 0.002). Conclusion: Hepatitis C patients have a high frequency of thyroid dysfunction, particularly primary hypothyroidism and subclinical hypothyroidism. Therefore, it is important to ensure regular screening for early prognosis and avoid treatment modalities that are known to cause thyroid abnormalities.
- Open Access
- 23 September 2021
- Published by Springer Nature in Cureus
- Vol. 13 (9)
Association of Plasma Omentin-1 Levels With Diabetes and Its Complications
Introduction: Plasma omentin-1 is a relatively new biomarker that has anti-diabetogenic and its level is inversely related with insulin resistance and diabetes mellitus, thus, increasing the risk of diabetic complications. In this study, we will determine the association between serum plasma omentin-1 levels and diabetes and its complications. Methods: This case control study was conducted from July 2020 to August 2021 in the internal medicine unit of a tertiary care hospital in Pakistan. There was a total of three groups, each comprising 250 patients. One group was type 2 diabetic patients with complications, the second group was type 2 diabetic patients without complications, and the third group was the control group, i.e. participants without type 2 diabetes. Their plasma omentin-1 levels were compared. Results: Patients with diabetic complications had significantly lower serum omentin levels than patients without complications (59.01 ± 9.21 ug/dL vs. 75.72 ± 14.11 ug/L; p-value: <0.0001). Patients with diabetes had significantly lower serum omentin levels in comparison to patients without diabetes (75.72 ± 14.11 ug/dL vs. 90.12 ± 17.89 ug/L; p-value: <0.0001). Conclusion: Based on our study, plasma omentin-1 is negatively associated with diabetes and its complications. Therefore, adequate levels of omentin-1 are needed in order to prevent diabetic complications.
- 23 September 2021
- Published by Springer Nature in Cureus
- Vol. 13 (9)
Open AccessAssociation of Plasma Omentin-1 Levels With Diabetes and Its Complications
Introduction: Plasma omentin-1 is a relatively new biomarker that has anti-diabetogenic and its level is inversely related with insulin resistance and diabetes mellitus, thus, increasing the risk of diabetic complications. In this study, we will determine the association between serum plasma omentin-1 levels and diabetes and its complications. Methods: This case control study was conducted from July 2020 to August 2021 in the internal medicine unit of a tertiary care hospital in Pakistan. There was a total of three groups, each comprising 250 patients. One group was type 2 diabetic patients with complications, the second group was type 2 diabetic patients without complications, and the third group was the control group, i.e. participants without type 2 diabetes. Their plasma omentin-1 levels were compared. Results: Patients with diabetic complications had significantly lower serum omentin levels than patients without complications (59.01 ± 9.21 ug/dL vs. 75.72 ± 14.11 ug/L; p-value: <0.0001). Patients with diabetes had significantly lower serum omentin levels in comparison to patients without diabetes (75.72 ± 14.11 ug/dL vs. 90.12 ± 17.89 ug/L; p-value: <0.0001). Conclusion: Based on our study, plasma omentin-1 is negatively associated with diabetes and its complications. Therefore, adequate levels of omentin-1 are needed in order to prevent diabetic complications.
- Open Access
- 23 September 2021
- Published by Springer Nature in Cureus
- Vol. 13 (9)
Prevalence of Thyroid Dysfunction in Newly Diagnosed Rheumatoid Arthritis Patients
Introduction: Rheumatoid arthritis (RA) is associated with various autoimmune disorders, including thyroid dysfunction. However, local data studying the prevalence of thyroid dysfunction in newly diagnosed RA patients are limited. Methods: This case-control study was conducted between January 2019 to December 2020 in the Internal Medicine Department of Liaquat University of Medical and Health Sciences. The study group of 400 newly diagnosed patients with RA was enrolled in the study. Another 400 patients without the diagnosis of RA, adjusted for age and gender, were enrolled in the study as a control group and their thyroid functions were compared. Results: Patients with RA had more participants with thyroid dysfunction compared to patients without RA (25.25% vs. 11.5%; p-value: 0.00001). In addition, more patients with RA had concomitant primary hypothyroidism compared to the control group (7.75% vs. 2.5%; p-value: 0.0007). Furthermore, patients with RA also had a higher prevalence of subclinical hypothyroidism (13.0% vs. 5.5%; p-value: 0.0002). Conclusion: Our study indicates that thyroid dysfunction is significantly prevalent in patients with RA. Based on our findings, it is suggested that management and follow-up of RA patients should include the screening of thyroid auto-antibodies and thyroid dysfunction.
- 23 September 2021
- Published by Springer Nature in Cureus
- Vol. 13 (9)
Open AccessPrevalence of Thyroid Dysfunction in Newly Diagnosed Rheumatoid Arthritis Patients
Introduction: Rheumatoid arthritis (RA) is associated with various autoimmune disorders, including thyroid dysfunction. However, local data studying the prevalence of thyroid dysfunction in newly diagnosed RA patients are limited. Methods: This case-control study was conducted between January 2019 to December 2020 in the Internal Medicine Department of Liaquat University of Medical and Health Sciences. The study group of 400 newly diagnosed patients with RA was enrolled in the study. Another 400 patients without the diagnosis of RA, adjusted for age and gender, were enrolled in the study as a control group and their thyroid functions were compared. Results: Patients with RA had more participants with thyroid dysfunction compared to patients without RA (25.25% vs. 11.5%; p-value: 0.00001). In addition, more patients with RA had concomitant primary hypothyroidism compared to the control group (7.75% vs. 2.5%; p-value: 0.0007). Furthermore, patients with RA also had a higher prevalence of subclinical hypothyroidism (13.0% vs. 5.5%; p-value: 0.0002). Conclusion: Our study indicates that thyroid dysfunction is significantly prevalent in patients with RA. Based on our findings, it is suggested that management and follow-up of RA patients should include the screening of thyroid auto-antibodies and thyroid dysfunction.